Author | Erin C. Strickland

Articles

Determination of the Relative Prevalence of Lurasidone Metabolites in Urine Using Untargeted HRMS

May 01, 2019

Special Issues

Article

For lurasidone treatment adherence testing, an untargeted high-resolution mass spectrometry method was employed, using known positive human urine samples to identify the lurasidone metabolites and their relative abundance in urine.

Liquid Chromatography Tandem Mass Spectrometry Method for Novel Psychoactive Substances: Kratom and Synthetic Cathinones in Urine

March 01, 2018

Special Issues

Article

A novel “dilute-and-shoot” LC–MS/MS method is described for the analysis of “bath salts” sold as “legal” highs, including mitragynine and nine synthetic cathinones, in urine.

A Rapid, Selective, and Sensitive Method for the Analysis of Naltrexone and 6β-Naltrexol in Urine

March 01, 2016

Special Issues

Article

Naltrexone (Depade, Re Via, Trexan) is a potent narcotic antagonist structurally similar to oxymorphone and naloxone. It blocks the subjective effects of heroin and other opiates and is primarily used in the management of opioid dependence and alcohol dependence. While conjugated 6β-naltrexol is the major urinary metabolite in man, conjugated naltrexone and free 6β-naltrexol are also major urinary species. To assist with monitoring substance abuse patients who are prescribed naltrexone, a rapid, selective, and sensitive LC–MS-MS method was developed to analyze for both naltrexone and 6β-naltrexol post-enzymatic hydrolysis. The validation of this method and some representative patient data are discussed in this report.

Development of a Fast LC–MS-MS Screen for Common Drugs of Abuse as an Alternative to Immunoassay Screening

March 01, 2015

Special Issues

Article

Enzyme immunoassay (EIA) is a conventional drug screening technique, but it can be limited by cross-reactivity that can lead to high false positive rates.